The relationships between CLDN17 and clinical pathological indicators were also analyzed, and the expression of CLDN17 was not associated with age (P = 1.000), HBsAg absent status (P = 1.000), cirrhosis (P = 1.000), serum AFP level (P = 0.637) of HCC patients or clinical staging (P = 1.000) of HCC patients. This evidence concerns the gene AFP and hepatocellular carcinoma.